Lantern Pharma (LTRN) Interest & Investment Income (2021 - 2026)
Lantern Pharma's (LTRN) quarterly Interest & Investment Income came in at $42160.0 in Q1 2026, down 71.85% YoY from $149790.0 in Q1 2025, and down 41.83% on a QoQ basis from $72475.0 in Q4 2025.
Lantern Pharma (LTRN) Interest & Investment Income (2021 - 2026) Analysis & Trends
Lantern Pharma (LTRN) has 6 years of Interest & Investment Income data on file, last reported at $42160.0 in Q1 2026.
- Quarterly Interest & Investment Income fell 71.85% year-over-year to $42160.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $330301.0 (down 52.21% YoY) and the FY2025 annual result came in at $437931.0, down 41.01% from the prior year.
- Interest & Investment Income slipped to $42160.0 in Q1 2026, from $72475.0 in the prior quarter.
- In the past five years, Interest & Investment Income ranged from a high of $267389.0 in Q4 2023 to a low of -$118572.0 in Q3 2022.
- A 5-year average of $120300.2 and a median of $117823.0 in 2023 frame the typical range for Interest & Investment Income.
- Annual changes were most pronounced in 2022 — Interest & Investment Income tumbled 253.55% — and 2023, when it jumped 496.68%.
- Tracing LTRN's Interest & Investment Income over 5 years: stood at $98395.0 in 2022, then jumped by 171.75% to $267389.0 in 2023, then slumped by 39.64% to $161393.0 in 2024, then tumbled by 55.09% to $72475.0 in 2025, then slumped by 41.83% to $42160.0 in 2026.
- The last three Interest & Investment Income figures came in at $42160.0 (Q1 2026), $72475.0 (Q4 2025), and $100921.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 120.60 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -48.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 48.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 67.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 27.90 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 28.14 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 115.94 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 10.98 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 5.13 Mn |
| 10 | Lantern Pharma | 26.05 Mn | 26.05 Mn | - | 42,160.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 42,160.00 |
| Dec 31, 2025 | 72,475.00 |
| Sep 30, 2025 | 100,921.00 |
| Jun 30, 2025 | 114,745.00 |
| Mar 31, 2025 | 149,790.00 |
| Dec 31, 2024 | 161,393.00 |
| Sep 30, 2024 | 191,352.00 |
| Jun 30, 2024 | 188,660.00 |
| Mar 31, 2024 | 200,950.00 |
| Dec 31, 2023 | 267,389.00 |
| Sep 30, 2023 | 246,394.00 |
| Jun 30, 2023 | 117,823.00 |
| Mar 31, 2023 | 133,782.00 |
| Dec 31, 2022 | 98,395.00 |
| Sep 30, 2022 | -118,572.00 |
| Jun 30, 2022 | 55,026.00 |
| Mar 31, 2022 | 22,421.00 |
| Dec 31, 2021 | -57,179.00 |
| Sep 30, 2021 | 77,219.00 |
| Jun 30, 2021 | 47,889.00 |